The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021
Open accessAbstract
Primary aldosteronism (PA) is associated with higher cardiovascular morbidity and mortality rates than essential hypertension. The Japan Endocrine Society (JES) has developed an updated guideline for PA, based on the evidence, especially from Japan. We should preferentially screen hypertensive patients with a high prevalence of PA with aldosterone to renin ratio ≥200 and plasma aldosterone concentrations (PAC) ≥60 pg/mL as a cut-off of positive results. While we should confirm excess aldosterone secretion by one positive confirmatory test, we could bypass patients with typical PA findings. Since PAC became lower due to a change in assay methods from radioimmunoassay to chemiluminescent enzyme immunoassay, borderline ranges were set for screening and confirmatory tests and provisionally designated as positive. We recommend individualized medicine for those in the borderline range for the next step. We recommend evaluating cortisol co-secretion in patients with adrenal macroadenomas. Although we recommend adrenal venous sampling for lateralization before adrenalectomy, we should carefully select patients rather than all patients, and we suggest bypassing in young patients with typical PA findings. A selectivity index ≥5 and a lateralization index >4 after adrenocorticotropic hormone stimulation defines successful catheterization and unilateral subtype diagnosis. We recommend adrenalectomy for unilateral PA and mineralocorticoid receptor antagonists for bilateral PA. Systematic as well as individualized clinical practice is always warranted. This JES guideline 2021 provides updated rational evidence and recommendations for the clinical practice of PA, leading to improved quality of the clinical practice of hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4061 · Cited by 2,925
Self-citationThe Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880 · cited 12×
“Endocrine Journal Advance Publication Endocrine Journal Advance Publication associated with aldosterone excess [4, 7, 77, 128].”
BackgroundMethodInfluentialSelf-citationMonticone, S., D'Ascenzo, F., Moretti, C., Williams, T. A., Veglio, F., Gaita, F., & Mulatero, P. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30319-4 · Cited by 1,072 · cited 3×
“In a meta-analysis, the risks of meta‐ bolic syndrome and diabetes mellitus were significantly higher in patients with PA than in patients with EH [12].”
BackgroundInfluentialPrimary aldosteronism: renaissance of a syndrome
Young, W. F. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02775.x · Cited by 680
Savard, S., Amar, L., Plouin, P.-F., & Steichen, O. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01060 · Cited by 505
Parthasarathy, H. K., Ménard, J., White, W. B., Young, W. F., Williams, G. H., Williams, B., Ruilope, L. M., McInnes, G. T., Connell, J. M., & MacDonald, T. M. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283455ca5 · Cited by 281
The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study
Brown, J. M., Robinson-Cohen, C., Luque-Fernandez, M. A., Allison, M. A., Baudrand, R., Ix, J. H., Kestenbaum, B., de Boer, I. H., & Vaidya, A. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0882 · Cited by 221 · cited 1×
“5 ng/mL/h) are at an elevated risk of later development of hypertension [152].”
Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion
Gerards, J., Heinrich, D. A., Adolf, C., Meisinger, C., Rathmann, W., Sturm, L., Nirschl, N., Bidlingmaier, M., Beuschlein, F., Thorand, B., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00299 · Cited by 112
Akehi, Y., Yanase, T., Motonaga, R., Umakoshi, H., Tsuiki, M., Takeda, Y., Yoneda, T., Kurihara, I., Itoh, H., Katabami, T., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1293 · Cited by 95
Self-citation
Cited by
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
Adler, G. K., Stowasser, M., Correa, R. R., Khan, N., Kline, G., McGowan, M. J., Mulatero, P., Murad, M. H., Touyz, R. M., Vaidya, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf284 · Cited by 355
Metadata
- Authors
- Naruse, M., Katabami, T., Shibata, H., Sone, M., Takahashi, K., Tanabe, A., Izawa, S., Ichijo, T., Otsuki, M., Omura, M., Ogawa, Y., Oki, Y., Kurihara, I., Kobayashi, H., Sakamoto, R., Satoh, F., Takeda, Y., Tanaka, T., Tamura, K., Tsuiki, M., Hashimoto, S., Hasegawa, T., Yoshimoto, T., Yoneda, T., Yamamoto, K., Rakugi, H., Wada, N., Saiki, A., Ohno, Y., & Haze, T.
- Venue
- Endocrine Journal
- Publisher
- Japan Endocrine Society
- Published
- 2022
- Volume
- 69
- Issue
- 4
- Pages
- 327-359
- ISSN
- 0918-8959 (ISSN-L)
- 1348-4540
- OpenAlex
- W4223989006
- Cited by
- 217
- References
- 9
- FWCI
- 28.46
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. https://app.cochat.ai/papers/10.1507/endocrj.ej21-0508
- The paper
- Naruse, M., Katabami, T., Shibata, H., Sone, M., Takahashi, K., Tanabe, A., Izawa, S., Ichijo, T., Otsuki, M., Omura, M., Ogawa, Y., Oki, Y., Kurihara, I., Kobayashi, H., Sakamoto, R., Satoh, F., Takeda, Y., Tanaka, T., Tamura, K., . . . Haze, T. (2022). Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocrine Journal. https://doi.org/10.1507/endocrj.ej21-0508
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.